

RUSSELL GLEN BUHR, MD, PhD
CURRICULUM VITAE

PERSONAL HISTORY

Research Office Address:

1100 Glendon Avenue
Suite 850-881, Box 739446
Los Angeles, California 90024
Phone (310) 267-2614
Fax (310) 794-0732

Administrative Office Address:

10833 Le Conte Avenue
43-229 CHS, Box 169017
Los Angeles, California 90095-1690
Phone (310) 825-5316
Fax (310) 206-8622

Clinical Office Addresses:

UCLA Pulmonary Disease Clinic
200 Medical Plaza, Suite 365-B
Los Angeles, California 90095
Phone (310) 825-8061
Fax (310) 794-9718

West Los Angeles Veterans Affairs Medical Center
11301 Wilshire Blvd (111Q), Bldg. 500, Rm. 3006
Los Angeles CA 90073
Phone (310) 478-3711 x48990
Fax (310) 268-4598

E-mail rbuhr@mednet.ucla.edu

russell.buhr@va.gov

EDUCATION

- Fall Semester 2005 New College, University of Oxford (Oxford Study Abroad Programme)
Oxford, United Kingdom
Associate Student – Public Health, History of the Protestant Reformation
- 2002 – 2006 Azusa Pacific University
Azusa, California
Bachelor of Arts (Honors) – Molecular Biology
- 2006 – 2010 Keck School of Medicine, University of Southern California
Los Angeles, California
Doctor of Medicine
- 2013 – 2014 Chief Medical Resident
Departments of Medicine
District of Columbia Veterans Affairs Medical Center; Washington, DC
MedStar Georgetown University Hospital; Washington, DC
- 2010 – 2013 Resident Physician (Internal Medicine)
Department of Medicine
MedStar Georgetown University Hospital; Washington, DC
- 2014 – 2017 Fellow Physician (Pulmonary & Critical Care Medicine)
Division of Pulmonary & Critical Care Medicine
UCLA Health System; Los Angeles, CA
- 2015 – 2019 Post-Doctoral Fellow in Health Services Research
Specialty Training and Research Program
UCLA Department of Medicine; Los Angeles, CA

2015 – 2019 Fielding School of Public Health, University of California, Los Angeles
Los Angeles, California
Doctor of Philosophy – Health Policy & Management
Dissertation: “Chronic Obstructive Pulmonary Disease and 30-day
Rehospitalizations: An Analysis of the Nationwide Readmissions
Database”
Committee Chairs: Carol Mangione, MD, MSPH & Michael Ong, MD, PhD
Committee Members: Steven Dubinett, MD & Gerald Kominski, PhD

LICENSURE

2011 – 2014 Medicine & Surgery, District of Columbia #MD039720
2011 – 2015 Medicine & Surgery, Virginia #0101250359
2014 – current Medicine & Surgery, California #A129932

BOARD CERTIFICATION

2013 – current Internal Medicine, American Board of Internal Medicine #355084
2016 – current Pulmonary Disease, American Board of Internal Medicine #355084
2017 – current Critical Care Medicine, American Board of Internal Medicine #355084

PROFESSIONAL EXPERIENCE

Present positions:

2018 – current Staff Physician
Section of Pulmonary, Critical Care, and Sleep Medicine
Greater Los Angeles Veterans Affairs Healthcare System

2018 – current Associate Investigator
Center for the Study of Innovation, Implementation, and Policy
Greater Los Angeles Veterans Affairs Healthcare System

2019 – current Assistant Professor of Medicine
Division of Pulmonary & Critical Care Medicine
David Geffen School of Medicine at University of California, Los Angeles

Prior positions:

2017 – 2019 Clinical Instructor of Medicine
Division of Pulmonary & Critical Care Medicine
David Geffen School of Medicine at University of California, Los Angeles

2013 – 2014 Clinical Instructor of Medicine
Department of Medicine
Georgetown University School of Medicine; Washington, DC

PROFESSIONAL ACTIVITIES

Committee Service

2003 – 2005 Student Honors Council, Azusa Pacific University

2006 – 2007 Class Co-President, Keck School of Medicine Class of 2010

2007 – 2008	Chapter Co-President, Keck School of Medicine American Medical Student Association
2008 – 2009	National Chair, Committee on Student Life American Medical Student Association
2009 – 2010	National Vice-President for Programming, National Board of Trustees Chairman of the Executive Board of Action Committees American Medical Student Association
2008 – 2009	University Senator/Vice-President for University Affairs Keck School of Medicine, University of Southern California
2011	Interim Alumni & Resident Trustee, National Board of Trustees American Medical Student Association
2011 – 2012	Dept. of Medicine Delegate, Graduate Medical Education Committee Georgetown University Hospital
2013 – 2014	Internal Medicine Residency Program Steering Committee Georgetown University Hospital
2013 – 2014	Resident Clinical Competency Committee Georgetown University Hospital
2015 – 2016	Resident Informaticist Program Ronald Reagan UCLA Medical Center
2017 – current	Fellowship Candidate Selection Committee Division of Pulmonary & Critical Care, David Geffen SOM at UCLA
2018 – current	Director, Pulmonary & Critical Care Center of Excellence Office of Health Informatics & Analytics, UCLA Health System
2018 – current	Pulmonary & Critical Care Quality Assurance Committee Division of Pulmonary & Critical Care, UCLA Health System
<u>Editorial Services</u>	
2016 – current	Abstract Reviewer, American College of Physicians National Conference
2017 – current	<i>Ad Hoc</i> Reviewer, Journal of Hospital Medicine
2019 – current	<i>Ad Hoc</i> Reviewer, Respiriology
2019 – current	<i>Ad Hoc</i> Reviewer, Journal of General Internal Medicine
<u>Professional Associations & Scholarly Societies</u>	
2006 – 2014	Member, American Medical Student Association

2006 – 2017	Member, American Medical Association
2007 – current	Member, American College of Physicians
2007 – current	Member, Physicians for Human Rights
2010 – current	Member, Institute for Healthcare Improvement
2012 – 2014	Member, Society for General Internal Medicine
2012 – current	Member, American Thoracic Society
2014 – current	Member, American College of Chest Physicians
2015 – 2019	Member, Academy Health
2018 – current	Member, European Respiratory Society

HONORS AND SPECIAL AWARDS

2006	Distinguished Honors Scholar Azusa Pacific University
2006	Outstanding Senior Scholar – Department of Biology & Chemistry Azusa Pacific University
2008	National LGBT Health Achievement Award American Medical Student Association
2010	Order of Areté Graduate Honor Society University of Southern California
2011	String of Pearls Resident Teaching Award Nominee Georgetown University School of Medicine
2013	Ambulatory Care Award Georgetown University Hospital
2013	Research Day Outstanding Clinical Vignette Georgetown University Hospital
2015	Fellow Teaching Award Nominee Ronald Reagan UCLA Medical Center
2017	Outstanding Research Abstract California Thoracic Society Annual Meeting
2017	3 rd Place Abstract – Clinical & Health Services Research (Junior Faculty) UCLA Department of Medicine Research Day

GRANTS, SCHOLARSHIPS, AND FELLOWSHIPS

Fellowships & Scholarships

2002 - 2006	Board of Trustees Finalist Scholarship, Azusa Pacific University
2002 – 2006	Science & Math Scholarship, Azusa Pacific University
2006 – 2010	Beverly Brines Memorial Scholarship, University of Southern California
2009 – 2010	University Guild Scholarship, University of Southern California
2015 – current	Specialty Training and Advanced Research (STAR) Fellowship Department of Medicine, University of California, Los Angeles

Active Research Grants & Fellowships

None

Completed Research Grants & Fellowships

Project:	Identifying risk for 30-day readmission after hospitalization for acute exacerbations of COPD
Source:	Loan Repayment Program (NIH/NHLBI)
Purpose:	This mixed-methods study serves to identify risk factors for rehospitalization after acute exacerbations of COPD in a two-hospital system, using both clinical data points and structured interviews to determine how disease severity, quality of care, and social support systems influence hospital readmissions.
Dates:	07/2016 – 07/2018
Role:	Principal Investigator (Supervisor: Michael Ong, MD, PhD)
Direct Cost:	N/A
Grant #:	L30HL134025
Project:	UCLA Clinical Translational Science Institute (TL1 Component)
Source:	NIH/NCATS
Purpose:	The goal of the UCLA CTSI TL1 program is to provide comprehensive training and experience in Type 4, community-partnered translational research (with a strong foundation in Type 3 translational research) to highly-qualified pre- and post-doctoral trainees.
Dates:	01/2017 – 12/2018
Role:	Post-doctoral fellow (PI: Moira Inkelas, PhD)
Direct Cost:	N/A
Grant #:	TL1TR001883-01

LECTURES AND PRESENTATIONS

Invited Lectures & Presentations

1. *Factors associated with 30-day readmission for COPD: A health system analysis* – Pulmonary Grand Rounds – UCLA Division of Pulmonary & Critical Care Medicine, Los Angeles, California - May 6, 2016
2. *Palliative Care and Advanced Care Planning in Advanced COPD* – Hospice and Palliative Medicine Core Lecture Series – West Los Angeles Veterans Affairs Medical Center, Los Angeles, California – September 14, 2018

3. *Bronchodilator-variable airways obstruction and COPD outcomes* – Subpopulations and Intermediate Outcomes in COPD Study Steering Committee Meeting – University of North Carolina, Durham – September 26, 2018
4. *Inspiratory capacity, physical performance, and survival* – Subpopulations and Intermediate Outcomes in COPD Study Steering Committee Meeting – University of Utah, Salt Lake City – April 5, 2019

TEACHING EXPERIENCE

DIDACTIC AND LABORATORY COURSES

- 2018 – current Oral & Systemic Diseases 102: Respiratory Physiology (Dental Students)
12 contact hours, 20 hours preparation time, 140 students
University of California Los Angeles, School of Dentistry
- 2018 – current Medicine 199: Guided Research (Undergraduates)
2 contact hours per week per student, 30 weeks per year, 5 students
University of California Los Angeles, David Geffen School of Medicine
- 2018 – current Human Body & Disease: Respiratory Physiology (Medical Students)
8 contact hours, 120 students
University of California Los Angeles, David Geffen School of Medicine

CLINICAL TEACHING

- 2017 – current Pulmonary Consultation Service (Fellows and Residents)
20 contact hours per week, 2 weeks per year
Ronald Reagan UCLA Medical Center and West Los Angeles Veterans
Affairs Medical Center
- 2017 – current Medical Intensive Care Unit (Fellows, Residents, and Medical Students)
40 contact hours per week, 8 weeks per year
Ronald Reagan UCLA Medical Center and West Los Angeles Veterans
Affairs Medical Center
- 2017 – current Pulmonary Disease Continuity Clinic (Fellows and Medical/NP Students)
5 contact hours per week, 40 weeks per year
UCLA Medical Specialty Suites
- 2018 – current Simulation Lab – Intensive Care Unit (Medical Students)
4 contact hours per student, 20 students per year
David Geffen School of Medicine at UCLA

ACTIVE RESEARCH STUDIES

Project: **Chronic Obstructive Pulmonary Disease and 30-day Hospital Readmission: An analysis of the Nationwide Readmission Database**

Funding: Internal/Departmental

IRB#: 18-001208

Purpose: COPD is the third leading cause of death worldwide and a major cause of morbidity and healthcare expenditures, primarily through hospitalization. About 20% of patients hospitalized for COPD exacerbations are readmitted to hospital within 30 days of discharge. This study aims to determine risk factors for hospital readmission, the nature and outcomes of readmissions, and to analyze the Centers for Medicare and Medicaid Services Hospital Readmission Reduction Program's impact on readmission rates and outcomes.

Dates: 2017 – 2019

Role: Principal Investigator

Project: **SPIROMICS II: Biological Underpinnings of COPD Heterogeneity and Progression**

Funding: NIH/NHLBI

Grant #: 1U01HL137880-01

IRB#: 18-000403

Purpose: COPD is heterogeneous and the factors that contribute to disease progression and exacerbations are poorly understood. This study will investigate whether a newly described clinical condition ("Smokers with symptoms despite preserved spirometry") progresses to COPD. This study will also investigate the mucus abnormalities, inflammatory pathways, and infectious processes that contribute to disease progression and exacerbations in heterogeneous patients with bona fide COPD. The ultimate goal will be to guide the development of therapeutics that target selected individuals with COPD based on their underlying biology.

Dates: 2017 – current

Role: Co-Investigator (PI: Prescott Woodruff, MD; Site PI: Christopher Cooper, MD)

Project: **RETHINC - REdefining Therapy IN early COPD**

Funding: NIH/NHLBI

Grant #: 1U01HL128952

IRB#: 17-000107

Purpose: This is a Phase 3, double-blind, placebo-controlled, parallel design multi-study comparing indacaterol/glycopyrrolate 27.5/15.6 mcg inhaled twice daily vs placebo in subjects with ≥ 20 pack-year smoking history with post-bronchodilator FEV₁/FVC ≥ 0.70 and CAT ≥ 10 . Treatment duration is 12 weeks. The drug is FDA approved for COPD, but not for subjects who do not meet the criteria for COPD, such as patients in this study. For this reason, the drug is deemed investigative.

Dates: 2017 – current

Role: Co-Investigator (PI: Prescott Woodruff, MD; Site PI: Igor Barjaktarevic, MD, PhD)

Project: **Intervention Study In OverweiGHT Patients with COPD (Insight COPD)**

Funding: NIH/NHLBI

Grant #: U01HL128954

IRB#: 16-002060

Purpose: This study will look at patients with COPD who are obese or overweight in association with tobacco smoking, poor health habits and cardiovascular disease. This is an evidence-based, self-directed, randomized lifestyle intervention trial that targets modest weight loss and increased physical activity among overweight and obese patients with COPD.

Dates: 2016 – current

Role: Co-Investigator (PI: Christopher Cooper, MD)

Project: **Identification of phenotypes in chronic obstructive pulmonary disease**

Funding: Amgen (investigator-initiated study)

Grant #: 231710

IRB#: 14-000748

Purpose: COPD is recognized to be a classic example of gene-environment interaction resulting in markedly heterogeneous disease with many different phenotypes (or outward clinical manifestations of the disease). Defining homogenous subpopulations with specific COPD phenotypes will better characterize COPD in its multiple manifestations. The definition of these phenotypes must link genomics, epigenomics, proteomics, and metabolomics to clinically meaningful patient characteristics that will lend themselves to specialized treatment approaches. Recent literature has identified several potential phenotypes for study in COPD. They are a) bronchitic, b) asthmatic, c) emphysematous, d) infective, e) bronchiectatic, f) exacerbator and g) debilitated. Identification of novel biomarker profiles will assist in the phenotyping of COPD patients but also provide means of tracking clinical progression over short term that might ultimately be predictive of clinically meaningful patient reported outcomes.

Dates: 2015 – current

Role: Co-Investigator (PI: Igor Barjaktarevic, MD, PhD)

COMPLETED STUDIES

Project: **Non-Invasive Monitoring Using Carotid Corrected Doppler Flow Time to Determine Fluid Responsiveness for Patients in Shock**

Funding: GE Healthcare (investigator-initiated study)

Purpose: This study compares the assessment of carotid corrected flow time (ccFT) change to other established methods for determining fluid responsiveness in hemodynamically (blood circulation) unstable patients in shock. This study aims to further explore the safety and feasibility of bedside ultrasound use in the non-invasive assessment of fluid responsiveness during the diagnosis and management of shock. This study involves a limited bedside ultrasound assessment of the neck and chest.

Dates: 2016 – 2018 (completion of study)

Role: Co-Investigator (PI: Igor Barjaktarevic, MD, PhD)

Project: **Phase 1/2 Study of Intravenous or Intrapleural Administration of a Serotype rh.10 Replication Deficient Adeno-associated Virus Gene Transfer Vector Expressing the Human Alpha-1 Antitrypsin cDNA to Individuals with Alpha-1 Antitrypsin Deficiency**

Funding: Adverum Biotechnologies

Contract #: N/A

IRB#: 17-001743

Purpose: Study ADVM-043-01 is a Phase 1/2, first-in-human study to test the safety and efficacy of ADVM-043 in subjects with alpha-1 antitrypsin deficiency. It is designed as an open label, multicenter dose-escalation study to evaluate the safety and protein expression of ADVM-043 by 2 routes of administration: in Part A, a single dose is to be administered by intravenous (IV) infusion to a limited number of subjects. Based on the safety and efficacy data from Part A, the study may proceed to Part B. AT this time only Part A will be initiated at UCLA. Part B will require an amendment and necessary approvals before any part B protocol procedures are conducted. This decision to initiate Part B will be made in consultation with the Study Primary Investigator. The successful completion of this study will provide critical safety and preliminary efficacy data to determine whether to proceed to a Phase 3 pivotal study. ADVM-043 is an investigational gene-therapy product that is intended to deliver a functional gene to the liver of patients with alpha-1 antitrypsin (A1AT) deficiency. These patients possess a mutation in the human A1AT gene that affects the production and normal functioning of A1AT protein, normally synthesized in the liver and secreted systemically. A1AT has been found to be most active in the lung, where it balances the activity of neutrophil elastase, an enzyme released in the setting of inflammation or infection. Unchecked enzymatic activity can lead to destruction of lung tissue. In many patients with A1AT deficiency, insufficient anti-neutrophil elastase activity results in early-onset emphysema.

Dates: 2017 – 2018 (sponsor ended study)

Role: Co-Investigator (PI: Igor Barjaktarevic, MD, PhD)

PUBLICATION / BIBLIOGRAPHY

ORCID Bibliography Link: <http://www.orcid.org/0000-0001-6159-7435>

NCBI Bibliography Link:

<https://www.ncbi.nlm.nih.gov/sites/myncbi/russell.buhr.1/bibliography/48494668/public/?sort=date&direction=descending>

RESEARCH PAPERS

RESEARCH PAPERS – PEER REVIEWED

1. Nathan SD, Fischer CP, Shlobin OA, **Buhr RG**, Ahmad S, Weir N, Brown AW. Outcomes after hospitalization in idiopathic pulmonary fibrosis patients: a cohort study. *Chest*. 2015 Jan;147(1):173-179. <https://doi.org/10.1378/chest.13-2424>.
2. Zider AD, Wang X, **Buhr RG**, Srichana W, Barjaktarevic IZ, Cooper CB. Reduced COPD exacerbation risk correlates with improved FEV₁: a meta-regression analysis. *Chest*. 2017 Sep;152(3):494-501. <https://doi.org/10.1016/j.chest.2017.04.174>.
3. Barjaktarevic IZ, Toppen WE, Hu SB, Aquije Montoya E, Ong S, **Buhr RG**, Wang TS, Joel ID, Chang SY, Elashoff D, Markovic D, Cannesson M. Ultrasound assessment of the change in carotid corrected flow time in fluid responsiveness in undifferentiated shock. *Critical Care Medicine*. 2018 Nov;46(11):e1040-e1046. <https://doi.org/10.1097/CCM.0000000000003356>
4. Arjomandi M, Zeng S, Barjaktarevic I, Bowler RP, **Buhr RG**, Cooper CB, Couper DJ, Curtis JL, Dransfield MT, Han MK, Hansel NN, Hoffman EA, Kanner RE, Krishnan JA, Paine R, Peters SP, Rennard SI, Woodruff PG. Radiographic Lung Volumes Predict Progression to COPD in Smokers with Preserved Spirometry in SPIROMICS. *Eur Respir J*. 2019 Aug 22. pii: 1802214. <https://doi.org/10.1183/13993003.02214-2018>

CASE REPORTS & SERIES – PEER REVIEWED

1. Sheth CT, Eshaghian P, **Buhr RG**. Constrictive bronchiolitis with pulmonary thrombosis associated with ulcerative colitis. *Proceedings of the Department of Medicine of UCLA*. 2018 Jan;21

RESEARCH PAPERS – PEER REVIEWED (IN PRESS)

CASE REPORTS & SERIES – PEER REVIEWED (IN PRESS)

None

RESEARCH PAPERS – PEER REVIEWED (SUBMITTED)

1. Barjaktarevic I, **Buhr RG**, Wang X, Hu SB, Couper DJ, Anderson W, Kanner RE, Paine R, Bhatt SP, Bhakta N, Arjomandi M, Kaner RJ, Pirozzi CS, Curtis JL, O'Neal WK, Woodruff PG, Han MK, Martinez FJ, Hansel NN, Barr RG, Wells JM, Ortega V, Hoffman EA, Doerschuk C, Kim V, Dransfield MT, Drummond MB, Bowler RP, Criner G, Christenson SA, Martinez C, Peters SP, Krishnan JA, Tashkin DP, Cooper CB. Clinical Significance of Bronchodilator Responsiveness in COPD: SPIROMICS Cohort Analysis. Submitted July 2019 to *International Journal of COPD*.

2. **Buhr RG**, Jackson NJ, Dubinett SD, Kominski GF, Ong MK, Mangione CM. Comorbidity and readmission risk in chronic obstructive pulmonary disease: a comparison of the Charlson and Elixhauser comorbidity indices. Submitted July 2019 to *BMC Health Services Research*.
3. **Buhr RG**, Jackson NJ, Dubinett SD, Kominski GF, Mangione CM, Ong MK. Factors associated with differential causes of readmission following exacerbations of chronic obstructive pulmonary disease. Submitted July 2019 to *Journal of General Internal Medicine*.
4. **Buhr RG**, Jackson NJ, Dubinett SD, Kominski GF, Ong MK, Mangione CM. Readmission rates in chronic obstructive pulmonary disease: effects of the Hospital Readmissions Reduction Program. Submitted in August 2019 to *JAMA*.

CASE REPORTS & SERIES – PEER REVIEWED (SUBMITTED)

None

RESEARCH PAPERS – NON-PEER REVIEWED

None

RESEARCH PAPERS – NON-PEER REVIEWED (IN PRESS)

None

RESEARCH PAPERS – NON-PEER REVIEWED (SUBMITTED)

None

CHAPTERS

CHAPTERS (PUBLISHED)

1. **Buhr RG**, Do TD. “Preventive health for gay, bisexual, and queer men” Chapter 10 in Schneider JS, Silenzio VMB, Erickson-Schroth L (eds.). *The GLMA Handbook on LGBT Health*, ABC-CLIO, Santa Barbara, CA, May 2019. ISBN 0313395659.

CHAPTERS (IN PRESS)

None

LETTERS TO THE EDITOR

None

REVIEWS

REVIEWS (PUBLISHED)

1. Hoesterey D, Daas N, Janssens W, Martinez FJ, **Buhr RG**, Cooper CB, Tashkin DP, Barjaktarevic I. Spirometric Indices of Early Airflow Obstruction in Individuals at Risk of Developing COPD: Spirometry Beyond FEV₁/FVC. *Respiratory Medicine*. 2019 Sep;156:58-68. <https://doi.org/10.1016/j.rmed.2019.08.004>

REVIEWS (IN PRESS)

None

EDITORIALS

1. Barjaktarevic I, Kaner R, **Buhr RG**, Cooper CB. Bronchodilator responsiveness or reversibility in asthma and COPD – a need for clarity. *International Journal of Chronic Obstructive Pulmonary Disease*. 2018(13):3511-3513.
<https://doi.org/10.2147/COPD.S183736>

PAPERS IN PREPARATION (RESEARCH COMPLETED)

None

ABSTRACTS

1. Armitage S, Pryor J, **Buhr RG**, Dingess H, Milhon JL. *Cellular localization of the turkey astrovirus (TASTV) ORF1A protein* - Oral presentation - West Coast Biological Sciences Undergraduate Research Conference - April 2005
2. **Buhr RG**, Holtz M, Bhatia R. *Development of an in-vitro fluorescence-based assay to detect BCR/ABL kinase activity in chronic myeloid leukemia* - Oral presentation - West Coast Biological Sciences Undergraduate Research Conference - April 2005
3. **Buhr RG**, Lagos VL, Santiago N, Lowstuter K, Edwards QT, MacDonald DJ, Weitzel JN, Palomares MR. *The effect of genetic cancer risk assessment on breast cancer risk perception and screening adherence in a cohort of unaffected women* - Poster presentation - San Antonio Breast Cancer Symposium - December 2006 [Breast Cancer Res Treat. 2006 Dec;100 Suppl 1:S182].
4. **Buhr RG**, Shlobin OA, Brown AW, Ahmad S, Weir NA, Nathan SD. *Treatment of pulmonary hypertension in COPD: Implications for exercise tolerance and mortality* - Poster presentation - American College of Chest Physicians National Meeting, Chicago, Illinois - October 2013 [Chest. 2013;144(4_MeetingAbstracts):853A. doi:[10.1378/chest.1700261](https://doi.org/10.1378/chest.1700261)]
5. **Buhr RG**, Shlobin OA, Brown AW, Ahmad S, Weir NA, Nathan SD. *Six-minute walk test pulse rate recovery as a predictor of pulmonary hypertension in COPD* - Poster presentation - American College of Chest Physicians National Meeting, Chicago, Illinois - October 2013 [Chest. 2013;144(4_MeetingAbstracts):689A. doi:[10.1378/chest.1701222](https://doi.org/10.1378/chest.1701222)]
6. **Buhr RG**, Zider AD, Barjaktarevic IZ, Ong MK, Cooper CB. *Factors associated with 30-day readmission for COPD: A health system analysis* - Poster presentation - American Thoracic Society International Meeting, San Francisco, California - May 2016 [Am J Respir Crit Care Med 193:A1112]
7. **Buhr RG**, Sheth CV. *Constrictive Bronchiolitis with Pulmonary Thrombus Associated With Ulcerative Colitis* - Poster presentation - American College of Chest Physicians National Meeting, Los Angeles, California - October 2016 [Chest. 2016;150(4_MeetingAbstracts):1057A. doi:[10.1016/j.chest.2016.08.1164](https://doi.org/10.1016/j.chest.2016.08.1164)]
8. **Buhr RG**, Chen, X, Tashkin DP, Cooper CB, Ong MK. *Readmissions for COPD and the interaction of hospital type and case mix comorbidity* - Poster presentation - California Thoracic Society Annual Meeting, Carmel, CA - January 2017
9. **Buhr RG**, Chen, X, Tashkin DP, Cooper CB, Ong MK. *Readmissions for COPD and the interaction of hospital type and case mix comorbidity* - Oral presentation - American

Thoracic Society International Meeting, Washington, DC - May 2017 [Am J Respir Crit Care Med 195:A7001]

10. **Buhr RG**, Chen, X, Tashkin DP, Cooper CB, Ong MK. *Readmissions for COPD and the interaction of hospital type and case mix comorbidity* - Poster presentation - UCLA Department of Medicine Research Day, Los Angeles, CA - October 2017
11. Dolezal BA, **Buhr RG**, Hsu N, Flynn MJ, Barjaktarevic IZ, Cooper CB. *The effect of altering breathing frequency on maximum voluntary ventilation* - Poster presentation - American Thoracic Society International Meeting, San Diego, California - May 2018 [Am J Respir Crit Care Med 2018;197:A5877]
12. **Buhr RG**, Richter SE, Hsu N, Flynn MJ, Barjaktarevic IZ, Cooper CB, Ong MK,. *A majority of readmissions after COPD hospitalization are not COPD-related: Implications for readmission reduction programs* - Poster presentation - American Thoracic Society International Meeting, San Diego, California - May 2018 [Am J Respir Crit Care Med 2018;197:A4978]
13. Saiphoklang N, Marzan-McGill R, Villareal M, Dembek M, Dolezal BA, **Buhr RG**, Hsu N, Flynn MJ, Belperio J, Cooper CB, Barjaktarevic IZ. *Stability in inflammatory biomarkers and functional performance in stable COPD* - Poster presentation - American Thoracic Society International Meeting, San Diego, California - May 2018 [Am J Respir Crit Care Med 2018;197:A3132]
14. Toppen W, Hu S, Aquije E, Ong S, **Buhr RG**, Wang TS, Joel I, Chang SY, Elashoff D, Markovic D, Barjaktarevic IZ. *Doppler evaluation of carotid corrected flow time in assessing fluid responsiveness in undifferentiated shock* - Poster presentation - American Thoracic Society International Meeting, San Diego, California - May 2018 [Am J Respir Crit Care Med 2018;197:A6011]
15. Flynn MJ, **Buhr RG**, Wang X, Lemaster WB, Dolezal B, Couper D, Anderson W, Kanner W, Paine R, Kaner R, Curtis J, O'Neal W, Woodruff P, Postow L, Han M, Martinez F, Garr G, Wells J, Ortega V, Peters S, Hoffman E, Doerschuk C, Kim V, Dransfield M, Bhatt S, Bhakta N, Drummond MB, Bowler R, Criner G, Pirozzi C, Martinez C, Cooper CB, Barjaktarevic I for the SPIROMICS investigators. *Reduced FEV3/FVC identifies smokers at risk of developing COPD in the SPIROMICS cohort* – Oral presentation – European Respiratory Society International Congress, Paris, France – September 2018 [European Respiratory Journal 2018 52: OA2152. doi:[10.1183/13993003.congress-2018.OA2152](https://doi.org/10.1183/13993003.congress-2018.OA2152)]
16. **Buhr RG**, Barjaktarevic IZ, Wang X, Dolezal B, Flynn MJ, Couper D, Anderson W, Paine R, Kaner R, Curtis J, O'Neal W, Woodruff P, Postow L, Han M, Martinez F, Barr G, Wells G, Ortega V, Hoffman E, Doerschuk C, Kim V, Dransfield M, Bhatt S, Bhakta N, Drummond MB, Bowler R, Criner C, Martinez C, Cooper CB, Kanner R for the SPIROMICS investigators. *Airflow obstruction which corrects post-bronchodilator as a predictor of future development of COPD* – Oral presentation - European Respiratory Society International Congress, Paris, France – September 2018 [European Respiratory Journal 2018 52: Suppl. 62, OA2153. doi:[10.1183/13993003.congress-2018.OA2153](https://doi.org/10.1183/13993003.congress-2018.OA2153)]

17. LeMaster WB, Markovic D, Ingersoll S, **Buhr RG**, Flynn MJ, Toppen W, Dembek M, Villarreal M, McGill R, Johnston JA, Belperio JA, Milenkovic B, Phee H, Cooper CB, Barjaktarevic I. *Significance of blood eosinophil count in stable COPD*. Poster presentation – American Thoracic Society International Conference, Dallas, Texas – May 2019

18. Arjomandi M, Zeng S, Barjaktarevic I, Barr RG, Bleecker ER, Bowler RP, **Buhr RG**, Comellas AP, Cooper CB, Couper D, Curtis JL, Dransfield MT, Han MK, Hansel NN, Hoffman EA, Kaner RJ, Kanner RE, Krishnan JA, Paine R, Peters SP, Rennard SI, Woodruff PG for the SPIROMICS investigators. *Radiographic lung volumes predict progression to COPD in smokers with preserved spirometry in SPIROMICS*. Oral presentation – American Thoracic Society International Conference, Dallas, Texas – May 2019

19. Saiphoklang N, Marzan-McGill R, Villarreal M, Dembek M, Dolezal B, **Buhr RG**, Flynn MJ, LeMaster WB, Belperio JA, Cooper CB, Barjaktarevic I. *Heart rate variability in COPD patients differs with chronic bronchitic and bronchiectatic phenotypes*. Poster presentation – American Thoracic Society International Conference, Dallas, Texas – May 2019

20. Awan O, **Buhr RG**, Kamdar BB. *Delirium...“Unable-to-Assess”? An electronic health record-based evaluation of inappropriate “unable-to-assess” confusion assessment method for the intensive care unit (CAM-ICU) documentation in a medical ICU*. Poster discussion – American Thoracic Society International Conference, Dallas, Texas – May 2019

21. Moughames E, Galiatsatos P, Woo H, Romero-Rivero K, Raju S, Hoffman EA, Ortega VE, Parekh T, Krishnan JA, Drummond MB, **Buhr RG**, Comellas AP, Couper D, Paine R, Paulin LM, Putcha N, Hansel NN. *Disparities in access to food and COPD-related outcomes*. Poster presentation – American Thoracic Society International Conference, Dallas, Texas – May 2019

22. Ronish B, Quibrera M, Barjaktarevic I, Cooper CB, Kanner RE, Pirozzi CS, Kim V, Wells JM, Han MK, Woodruff PG, Ortega VE, Peters SP, Hoffman EA, **Buhr RG**, Dolezal BA, Liou TG, Bateman L, Schroeder JD, Couper D, Paine R. *Reduced maximum mid-expiratory flow is independently associated with computed tomography measures of smoking-related lung disease in the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS) Cohort* - Poster presentation – American Thoracic Society International Conference, Dallas, Texas – May 2019